Neuroendocrine cell differentiation in the CWR22 human prostate cancer xenograft: Association with tumor cell proliferation prior to recurrence

Prostate

Volumn 60, Issue 2, 2004, Pages 91-97

  Huss, Wendy J ^a   Gregory, Christopher W ^a,b   Smith, Gary J ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

CWR22 xenograft; Neuroendocrine cell; Prostate cancer

Indexed keywords

ANDROGEN; CELL MARKER; GROWTH FACTOR; KI 67 ANTIGEN; NEUROPEPTIDE; SYNAPTOPHYSIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MODEL; CANCER RECURRENCE; CASTRATION; CELL COUNT; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; HORMONE DEFICIENCY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NEUROSECRETORY CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR CELL; TUMOR VASCULARIZATION;

ANDROGEN ANTAGONISTS; ANIMALS; CASTRATION; CELL DIFFERENTIATION; CELL DIVISION; CELL SURVIVAL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, NUDE; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

EID: 2942565608     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20032     Document Type: Article

References (37)

1. Nakada SY, di Sant'Agnese PA, Moynes RA, Hiipakka RA, Liao S, Cockett AT, Abrahamsson PA. The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue. Cancer Res 1993;53(9):1967-1970.
2. Speights VO Jr., Cohen MK, Riggs MW, Coffield KS, Keegan G, Arber DA. Neuroendocrine stains and proliferative indices of prostatic adenocarcinomas in transurethral resection samples. Br J Urol 1997;80(2):281-286.
3. Ahlgren G, Pedersen K, Lundberg S, Aus G, Hugosson J, Abrahamsson PA. Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment. Prostate 2000;42(4):274-279.
4. Aprikian AG, Cordon-Cardo C, Fair WR, Zhang ZF, Bazinet M, Hamdy SM, Reuter VE. Neuroendocrine differentiation in metastatic prostatic adenocarcinoma. J Urol 1994;151(4):914-919.
5. Ather MH, Abbas F. Prognostic significance of neuroendocrine differentiation in prostate cancer. Eur Urol 2000;38(5):535-542.
6. Bollito E, Berruti A, Bellina M, Mosca A, Leonardo E, Tarabuzzi R, Cappia S, Ari MM, Tampellini M, Fontana D, Gubetta L, Angeli A, Dogliotti L. Relationship between neuroendocrine features and prognostic parameters in human prostate adenocarcinoma. Ann Oncol 2001;12(Suppl 2):S159-S164.
7. Segawa N, Mori I, Utsunomiya H, Nakamura M, Nakamura Y, Shan L, Kakudo K, Katsuoka Y. Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer. Pathol Int 2001;51(6):452-459.
8. Cheville JC, Tindall D, Boelter C, Jenkins R, Lohse CM, Pankratz VS, Sebo TJ, Davis B, Blute ML. Metastatic prostate carcinoma to bone: Clinical and pathologic features associated with cancer-specific survival. Cancer 2002;95(5):1028-1036.
9. Sciarra A, Mariotti G, Gentile V, Voria G, Pastore A, Monti S, et al. Neuroendocrine differentiation in human prostate tissue: Is it detectable and treatable? BJU Int 2003;91(5):438-445.
10. Grobholz R, Bohrer MH, Siegsmund M, Junemann KP, Bleyl U, Woenckhaus M. Correlation between neovascularisation and neuroendocrine differentiation in prostatic carcinoma. Pathol Res Pract 2000;196(5):277-284.
11. di Sant'Agnese PA. Neuroendocrine differentiation in prostatic carcinoma: An update on recent developments. Ann Oncol 2001;12(Suppl 2):S135-S140.
12. Wainstein MA, He F, Robinson D, Kung HJ, Schwartz S, Giaconia JM, Edgehouse NL, Pretlow TP, Bodner DR, Kursh ED, et al. CWR22: Androgen-dependent xenograft model derived from a primary human prostatic carcinoma. Cancer Res 1994;54(23):6049-6052.
13. Nagabhushan M, Miller CM, Pretlow TP, Giaconia JM, Edgehouse NL, Schwartz S, Kung HJ, de Vere White RW, Gumerlock PH, Resnick MI, Amini SB, Pretlow TG. CWR22: the first human prostate cancer xenograft with strongly androgen-dependent and relapsed strains both in vivo and in soft agar. Cancer Res 1996;56(13):3042-3046.
14. Kim D, Gregory CW, French FS, Smith GJ, Mohler JL. Androgen receptor expression and cellular proliferation during transition from androgen-dependent to recurrent growth after castration in the CWR22 prostate cancer xenograft. Am J Pathol 2002;160(1):219-226.
15. Gregory CW, Hamil KG, Kim D, Hall SH, Pretlow TG, Mohler JL, French FS. Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res 1998;58(24):5718-5724.
16. Grimwood RE, Ferris CF, Nielsen LD, Huff JC, Clark RA. Basal cell carcinomas grown in nude mice produce and deposit fibronectin in the extracellular matrix. J Invest Dermatol 1986;87(1):42-46.
17. Helpap B, Kollermann J. Immunohistochemical analysis of the proliferative activity of neuroendocrine tumors from various organs. Are there indications for a neuroendocrine tumor-carcinoma sequence? Virchows Arch 2001;438(1):86-91.
18. Bosman FT. Neuroendocrine cells in non-endocrine tumors: What does it mean? Verh Dtsch Ges Pathol 1997;81:62-72.
19. Bonkhoff H, Wernert N, Dhom G, Remberger K. Relation of endocrine-paracrine cells to cell proliferation in normal, hyperplastic, and neoplastic human prostate. Prostate 1991;19(2):91-98.
20. Bonkhoff H, Stein U, Remberger K. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. Hum Pathol 1995;26(2):167-170.
21. Segal NH, Cohen RJ, Haffejee Z, Savage N. BCL-2 protooncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell. Arch Pathol Lab Med 1994;118(6):616-618.
22. Xue Y, Verhofstad A, Lange W, Smedts F, Debruyne F, de la Rosette J, Schalken J. Prostatic neuroendocrine cells have a unique keratin expression pattern and do not express Bcl-2: Cell kinetic features of neuroendocrine cells in the human prostate. Am J Pathol 1997;151(6):1759-1765.
23. Shen R, Dorai T, Szaboles M, Katz AE, Olsson CA, Buttyan R. Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormone-depleted medium. Urol Oncol 1997;3:67-75.
24. Burchardt T, Burchardt M, Chen MW, Cao Y, de la Taille A, Shabsigh A, Hayek O, Dorai T, Buttyan R. Transdifferentiation of prostate cancer cells to a neuroendocrine cell phenotype in vitro and in vivo. J Urol 1999;162(5):1800- 1805.
25. Bang YJ, Pirnia F, Fang WG, Kang WK, Sartor O, Whitesell L, Ha MJ, Tsokos M, Sheahan MD, Nguyen P, et al. Terminal neuroendocrine differentiation of human prostate carcinoma cells in response to increased intracellular cyclic AMP. Proc Natl Acad Sci USA 1994;91(12):5330-5334.
26. Cox ME, Deeble PD, Lakhani S, Parsons SJ. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: Implications for prostate cancer progression. Cancer Res 1999;59(15):3821-3830.
27. Spiotto MT, Chung TD. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate 2000;42(3):186-195.
28. Zelivianski S, Verni M, Moore C, Kondrikov D, Taylor R, Lin MF. Multipathways for transdifferentiation of human prostate cancer cells into neuroendocrine-like phenotype. Biochim Biophys Acta 2001;1539(1-2):28-43.
29. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, Schroder FH, van Steenbrugge GJ. Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model. Am J Pathol 1999;154(2):543-551.
30. Jongsma J, Oomen MH, Noordzij MA, Van Weerden WM, Martens GJ, van der Kwast TH, Schroder FH, van Steenbrugge GJ. Different profiles of neuroendocrine cell differentiation evolve in the PC-310 human prostate cancer model during long-term androgen deprivation. Prostate 2002;50(4):203-215.
31. Masumori N, Thomas TZ, Chaurand P, Case T, Paul M, Kasper S, Caprioli RM, Tsukamoto T, Shappell SB, Matusik RJ. A probasin-large T antigen transgenic mouse line develops prostate adenocarcinoma and neuroendocrine carcinoma with metastatic potential. Cancer Res 2001;61(5):2239-2249.
32. Kaplan-Lefko PJ, Chen TM, Ittmann MM, Barrios RJ, Ayala GE, Huss WJ, Maddison LA, Foster BA, Greenburg NM. Pathobiology of autochthonous prostate cancer in a pre-clinical transgenic mouse model. Prostate 2003;55(3):219-237.
33. Gregory CW, Johnson RT Jr., Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001;61(7):2892-2898.
34. Hansson J, Abrahamsson PA. Neuroendocrine pathogenesis in adenocarcinoma of the prostate. Ann Oncol 2001;12(Suppl 2):S145-S152.
35. Harper ME, Glynne-Jones E, Goddard L, Thurston VJ, Griffiths K. Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. Br J Cancer 1996;74(6):910-916.
36. Iwamura M, Koshiba K, Cockett AT. Receptors for BPH growth factors are located in some neuroendocrine cells. Prostate Suppl 1998;8:14-17.
37. Dai J, Shen R, Sumitomo M, Stahl R, Navarro D, Gershengorn MC, Nanus DM. Synergistic activation of the androgen receptor by bombesin and low-dose androgen. Clin Cancer Res 2002;8(7):2399-2405.